Second Genome and the Mayo Clinic Center for Individualized Medicine are teaming up to create new therapies based on research of the microbiome.
The collaboration goes hand in hand with Second Genome’s new treatment expansion for diseases that include inflammatory bowel disease, metabolic disorders, and colorectal cancer. The company, with its focus on treatment development through the microbiome, sees the partnership as a step forward in its continual research of the bacteria collection.
When Second Genome identifies conditions it believes the microbiome is associated with, the Mayo Clinic will provide human samples for Second Genome to analyze. Therapies will then be developed based on any findings.
“The importance of the microbiome in a wide range of diseases is increasingly obvious,” Second Genome CEO Peter DiLaura said in a release. “We believe that the combined expertise of Second Genome and the world-class clinicians and researchers at Mayo Clinic will accelerate our ability to discover and develop new transformative therapies that improve the lives of patients.”
For more information on the complexities of the microbiome, read “Change Your Microbiome, Change Yourself” from our spring issue.